← Eichor
Condition: Adenocarcinoma Of The Prostate Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Adenocarcinoma Of The Prostate

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Computed Tomography-Guided Stereotactic Body Radiation Therapy With Intrafraction Motion Monitoring for the Treatment of
NA · 1 location(s) · Jonsson Comprehensive Cancer Center · NCT06995053Feasibility of MR-Informed Adaptive Marker-less SBRT in Patients With Bilateral Hip Prostheses Undergoing SBRT for Local
NA · 1 location(s) · University of Zurich · NCT07042256Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer
Phase 2 · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT06330805Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy
Phase 4 · 1 location(s) · OHSU Knight Cancer Institute · NCT05919329Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05616650A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Phase 1/Phase 2 · 15 location(s) · Phanes Therapeutics · NCT05652686Extraperitoneal SINgle-port rObotic-assisted Radical Prostatectomy (RARP) Versus Transperitoneal Multi-port RARP in the
NA · 1 location(s) · Shanghai Changzheng Hospital · NCT06238713Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response
NA · 1 location(s) · University Health Network, Toronto · NCT06831032ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
Phase N/A · 3 location(s) · Duke University · NCT06141993A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Phase 1 · 8 location(s) · Bristol-Myers Squibb · NCT06067841A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male P
Phase 1/Phase 2 · 25 location(s) · AstraZeneca · NCT07192614Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
Phase 1 · 8 location(s) · Acerand Therapeutics (Hong Kong) Limited · NCT06801236ABlative Radiotherapy (for) Unfavorable Prostate Tumors 2.0
Phase N/A · 1 location(s) · University of Milano Bicocca · NCT07407608The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC)
Phase 2 · 2 location(s) · University Medical Center Groningen · NCT07038304Personalized Optimization of Systematic Prostate Biopsy
NA · 1 location(s) · Fujian Medical University Union Hospital · NCT05998278At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 · 2 location(s) · Mayo Clinic · NCT05969860The Use of Ultrasound in Assessing Post-prostatectomy Erectile Dysfunction
NA · 1 location(s) · Mayo Clinic · NCT05109208Measuring Oncological Value of Exercise and Statin
Phase 3 · 1 location(s) · Tampere University Hospital · NCT05796973Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT04734730SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
Phase 3 · 6 location(s) · Mayo Clinic · NCT06205316Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Prostate Cancer
Phase N/A · 1 location(s) · Mayo Clinic · NCT06470750Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Phase 3 · 338 location(s) · SWOG Cancer Research Network · NCT03678025Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
Phase 2 · 31 location(s) · Dendreon · NCT06134232Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Can
Phase 2 · 13 location(s) · National Cancer Institute (NCI) · NCT05691465Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonanc
Phase 4 · 51 location(s) · Guerbet · NCT04373564PSMA PET Response Guided SabR in High Risk Pca
Phase 1 · 2 location(s) · University of Texas Southwestern Medical Center · NCT06044857Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer
Phase 1 · 1 location(s) · Beijing Biotech · NCT07641049Nutrition and Exercise Interventions for Androgen Deprivation Therapy-Induced Obese Frailty in Elderly and Non-Elderly S
NA · 1 location(s) · Roswell Park Cancer Institute · NCT03880422Two-Fraction Ultrahypofractionated Radiotherapy With Focal Boost for Intermediate Risk, Localized Prostate Cancer
NA · 1 location(s) · UMC Utrecht · NCT06518226PSMA Guided Approach for bIoCHEmical Relapse After Prostatectomy-PSICHE
Phase N/A · 1 location(s) · Azienda Ospedaliero-Universitaria Careggi · NCT05022914
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.